课题基金 / 基金详情

PHASE IIA TO EVALUATE LUNG BIOEFFICACY OF DMP777 IN ADULTS W/ Cystic Fibrosis

PHASE IIA TO EVALUATE LUNG BIOEFFICACY OF DMP777 IN ADULTS W/ Cystic Fibrosis
IIA 期评估 DMP777 在患有囊性纤维化的成人中的肺生物功效
批准号:
6264332
负责人:
RICHARD Barry MOSS
金额:
$0.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

RICHARD Barry MOSS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cystic fibrosis, a common lethal genetic disorder, is characterized by a neutrophilic inflammatory exudate in the airways which causes bronchiectasis and eventual respiratory failure. Neutrophil elastase is believed to mediate many of the pathologic processes such as destruction of airway supporting tissue, mucus hypersecretion, opsonic deficiency, and cytokine secretion. DMP777 is a synthetic monobactam that penetrates the neutrophil to inhibit both intra- and extracellular elastase in a selective and essentially irreversible fashion. This study is a dose-escalating protocol to examine safety, pharmacokinetics, and pharmacodynamics of DMP777 in patients with CF by direct measurement of drug levels and elastase inhibition in bronchoalvolar fluids.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE I/II, SINGLE-CENTER, BLINDED, RANDOMIZED, CONTROLLED STUDY OF XOLAIR
  • 批准号:
    7605198
  • 项目类别:
  • 资助金额:
    $0.82万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
CLINICAL TRIAL: VX-770 CFTR ACTIVITY IN CYSTIC FIBROSIS (CF) SUBJECTS WITH GENOT
  • 批准号:
    7717937
  • 项目类别:
  • 资助金额:
    $0.1万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS
  • 批准号:
    7605255
  • 项目类别:
  • 资助金额:
    $1.4万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
CLINICAL TRIAL: XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WIT
  • 批准号:
    7717865
  • 项目类别:
  • 资助金额:
    $0.03万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
海外基金